T. Rowe Price Associates
TVGN icon

T. Rowe Price Associates’s Tevogen Inc TVGN Stock Holding History

T. Rowe Price Associates’s Portfolio TVGN Stock Details TVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-373
Closed -$7K – 3197
2025
Q4 		$7K Hold
373
– – ﹤0.01% 3088
2025
Q3 		$15K Hold
373
– – ﹤0.01% 3041
2025
Q2 		$24K Buy
+373
New +$21.2K ﹤0.01% 3044

Other funds holding TVGN

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

T. Rowe Price Associates's TVGN Position: Q1 2026 in Review

T. Rowe Price Associates sold out of Tevogen Inc (TVGN) in Q1 2026, closing a stake of 373 shares — an estimated $7K sold.

T. Rowe Price Associates first reported a position in TVGN in Q2 2025 and held it in 3 quarters. The position peaked at $24K in Q2 2025. 30 funds tracked by Wall St. Rank hold TVGN as of Q1 2026.

  • T. Rowe Price Associates reported no remaining Tevogen Inc position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 373 Tevogen Inc shares in Q1 2026, an estimated $7K.
  • T. Rowe Price Associates first reported a position in Tevogen Inc in Q2 2025 and held it in 3 quarters.
  • T. Rowe Price Associates's Tevogen Inc position peaked at $24K in Q2 2025.
  • 30 funds tracked by Wall St. Rank held Tevogen Inc as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.